At present, it is relatively clear that the risk factors of ICI-induced myocarditis are the concurrent use of ICIs with other cardiotoxic drugs [104], and the treatment of anti-PD-1/PD-L1 coupled with anti-CTLA-4 may be the strongest risk factor. Here, CTLA4 is linked to myocarditis.